GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Evonile Pharma Ltd

Evonile Pharma Approves Rights Issue Up to INR 9,000 Million

FUNDRAISE ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 04 Nov 2026, 07:15 PM IST  ·  BSE ID: e72b5ab0-bfba-4e59-bfc7-560104e21e52
View Original BSE Filing (PDF)
💡
In Simple Terms
The company is offering new shares to existing shareholders to raise funds.
🤖 AI Summary
  • Evonile Pharma approved a rights issue to raise up to INR 9,000 million.
  • Partly paid equity shares will be issued to eligible equity shareholders.
  • A Rights Issue Committee will finalize terms like record date and issue price.
  • Board also approved payment schedule and utilization of issue proceeds.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Aggregate amount to be raised via Rights Issue
₹ 9,000 million
🏢 How This Affects the Company
📈
Business Impact
This rights issue is intended to provide capital, potentially for expansion or debt reduction, impacting future business operations and growth prospects.
💰
Financial Impact
The fundraising will increase equity capital and cash reserves. The terms of the partly paid shares will influence future cash flows and balance sheet structure.
⚠️
Risk Impact
The success of the rights issue and subsequent payment by shareholders are crucial for realizing the intended financial benefits.
👥 What This Means For Shareholders
✅
Action Required
Shareholders should await further communication regarding the rights issue terms, including the record date and subscription process.
👤
Who Is Affected
All eligible equity shareholders as of the forthcoming record date will have the opportunity to participate in the rights issue.
🔍
Management Signal
The decision to launch a rights issue signals management's intent to raise substantial capital to fund company initiatives.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Finalization of rights issue terms by the Committee.
Announcement of the record date for the rights issue.
Dispatch of Letter of Offer to eligible shareholders.
MEDIUM RISK Rights issues carry market risk and dependent on shareholder participation and timely payments.
💡 Investor Takeaway
Evonile Pharma's Board approved a rights issue to raise up to INR 9,000 million via partly paid equity shares for eligible shareholders. Details like record date are pending.
⚖️ Strengths & Concerns

✅ Positives

  • Company is pursuing a significant INR 9,000 million capital raise via rights issue.
  • Board has approved the mechanism and delegated authority for finalizing rights issue terms.
❓ Frequently Asked Questions
What did Evonile Pharma's Board approve on November 4, 2026?
The Board approved the issuance of partly paid equity shares by way of a rights issue to raise up to INR 9,000 million.
What is the total amount Evonile Pharma plans to raise through the rights issue?
Evonile Pharma plans to raise an aggregate amount of up to ₹ 9,000 million through the rights issue.
Who is eligible to participate in Evonile Pharma's rights issue?
The rights issue will be offered to the eligible equity shareholders of Evonile Pharma Limited.
Which committee will decide the terms of the rights issue?
The 'Rights Issue Committee' has been authorized to decide terms including the record date, issue price, and entitlement ratio.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.